Phase I trial of oral 2'-deoxy-2'-methylidenecytidine: On a daily x 14- day schedule

Clinical Cancer Research

Volumn 6, Issue 6, 2000, Pages 2288-2294

  Masuda, Noriyuki ^a   Matsui, Kaoru ^a   Yamamoto, Nobuyuki ^b   Nogami, Toshiji ^b   Nakagawa, Kazuhiko ^b   Negoro, Shunichi ^c   Takeda, Kouji ^c   Takifuji, Nobuhide ^c   Yamada, Masaji ^d   Kudoh, Shinzoh ^d   Okuda, Teruyoshi ^e   Nemoto, Shinjiroh ^e   Ogawa, Kanako ^e   Myobudani, Hiroshi ^e   Nihira, Shinichi ^e   Fukuoka, Masahiro ^b  

^a OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OSAKA CITY GENERAL HOSPITAL   (Japan)

^d OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e NIPPON ROCHE RESEARCH CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXY 2' METHYLIDENECYTIDINE; ANTINEOPLASTIC AGENT; CYTIDINE DERIVATIVE; GEMCITABINE; RO 09 3431; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DOSE CALCULATION; DRUG STRUCTURE; FEMALE; HUMAN; MALAISE; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DEOXYURIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; TIME FACTORS;

EID: 0034044789     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Takenuki, K., Matsuda, A., Veda, T., Sasaki, T., Fujii, A., and Yamagami, K. Design, synthesis, and antineoplastic activity of 2′-deoxy-2′-methylidenecytidine. J. Med. Chem., 31: 1063-1064, 1988.
2. Matsuda, A., Azuma, A., Nakajima, Y., Takenuki, K., Dan, A., Iino, T., Yoshimura, Y., Minakawa, N., Tanaka, M., and Sasaki, T. Design of new types of antitumor nucleosides: the synthesis and antitumor activity of 2′-deoxy-(2′-C-substituted) cytidines. In: C. K. Chu and D. C. Baker (eds.), Nucleosides and Nucleotides As Antitumor Antiviral Agents, pp. 1-22. New York: Plenum Press, 1993.
3. Ono, T. Cellular uptake and cell kill kinetics of an antineoplastic nucleoside, 1-(2-deoxy-2-methylene-β-D-erythro-pentofuranosyl)cytosine. Biochem Pharmacol., 52: 1279-1285, 1996.
4. Elford, H., Freese, M., Passamani, E., and Morris, H. Ribonucleotide reductase and cell proliferation. J. Biol Chem., 245: 5228-5233, 1970.
5. Yamagami, K., Fujii, A., Arita, M., Okamoto, T., Sakata, S., Matsuda, A., Ueda, T., and Sasaki, T. Antitumor activity of 2′-deoxy-2′-methylidenecytidine, a new 2′-deoxycytidine derivative. Cancer Res., 51: 2319-2323, 1991.
6. Bouffard, D. Y., Laliberte, J., and Momparler, R. L. Kinetic studies on 2′,2′-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem. Pharmacol., 45: 1857-1861, 1993.
7. Miwa, M., Eda, H., Ura, M., F.-Ouchi, K., Keith, D. D., Foley, L. H., and Ishitsuka, H. High susceptibility of human cancer xenografls with higher levels of cytidine deaminase to a 2′-deoxycytidine antimetabolite, 2′-deoxy-2′-methylidenecytidine. Clin. Cancer Res., 493-497, 1998.
8. Eda, H., Ura, M., F.-Ouchi, K., Tanaka, Y., Miwa, M., and Ishitsuka, H. The antiproliferative activity of DMDC is modulated by inhibition of cytidine deaminase. Cancer Res., 58: 1165-1169, 1998.
9. Protodigm, L. Investigational Drug Brochure Ro 09-3431 DMDC, 2′-Deoxy-2′-methylidenecytidine. Tokyo, Japan: Nippon Roche Co., Ltd., 1998.
10. Mountain, C. F. A new international staging system for lung cancer. Chest, 89: 225S-233S, 1986.
11. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva, Switzerland: World Health Organization, 1979.
12. Abbruzzese, J. L., Grunewald, R., Weeks, E. A., Gravel, D., Adams, T., Nowak, B., Mineishi, S., Tarassoff, P., Satterlee, W., Raber, M. N., and Plunkett, W. A Phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J. Clin. Oncol., 9: 491-498, 1991.
13. Poplin, E. A., Corbett, T., Flaherty, L., Tarasoff, P., Redman, B. G., Valdivieso, M., and Baker, L. Difluorodeoxycytidine (dFdC)-gemcitabine: a Phase I study. Investig. New Drugs, 10: 165-170, 1992.
14. O'Rourke, T. J., Brown, T. D., Havlin, K., Kuhn, J. G., Craig, J. B., Burris, H. A., Satterlee, P. G., Tarassoff, P. G., and Von Hoff, D. D. Phase I clinical trial of gemcitabine given as intravenous bolus on 5 consecutive days. Eur. J. Cancer, 30A: 417-418, 1994.
15. Anderson, H., Thatcher, N., Walling, J., and Hansen, H. A Phase I study of a 24-hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br. J. Cancer, 74: 460-462, 1996.
16. Abratt, R. P., Bezwoda, W. R., Falkson, G., Goedhals, L., Hacking, D., and Rugg, T. A. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a Phase II study. J. Clin Oncol., 12: 1535-1540, 1994.
17. Anderson, H., Lund, B., Bach, F., Thatcher, N., Walling, J., and Hansen, H. H. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a Phase II study. J. Clin. Oncol., 12: 1821-1826, 1994.
18. Gemma, A., Kudoh, S., Fukuoka, M., Kurita, Y., Hasegawa, K., Harada, M., Mori, K., Ariyoshi, Y., Kurihara, M., Furuse, K., Horikoshi, N., Kanamaru, R., Furuyama, N., Yoneda, S., Furue, H., Taguchi, T., Ota, K., Wakui, A., Tsukagoshi, S., and Niitani, H. Phase I study on DMDC. Gann-to-Kagakuryoho, 23: 1799-1811, 1996.
19. van der Gaast, A., Woll, P. J., Planting, A., Gordon, R. J., Brindley, C., Devlin, J. A., Miller, R. M., Verweij, J., and Carmichael, J. A Phase I and pharmacokinetic study of oral 2′-deoxy-2′-methylidenecytidine (DMDC). Proc. Am. Soc. Clin. Oncol., 17: 191a, 1998.
20. Masuda, N., Negoro, S., Takeda, K., Takifuji, N., Hirashima, T., Yana, T., Kurata, N., Kuwabara, T., Kobayashi, S., Kudoh, S., Matsui, K., Takada, M., and Fukuoka, M. Phase I and pharmacologic study of oral (E)-2′-deoxy-2′-(fluoromethylene)cytidine: on a daily × 5-day schedule. Investig. New Drugs, 16: 245-254, 1999.